Overview
CALC market data
Price History
CALC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.97 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.46 – $7.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $20.3M · P/B 3.31.
Company News
CalciMedica Q2 EPS $(0.45) Misses $(0.28) EstimateBenzinga · Aug 11, 2026, 11:28 AM
8-K filing — CalciMedica, Inc. (CALC)SEC EDGAR · Aug 11, 2026, 11:15 AM
Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute PancreatitisBenzinga · Jul 29, 2026, 11:12 AM
CalciMedica Files Prospectus For Resale Of Up To 56,020,287 SharesBenzinga · Jul 24, 2026, 8:18 PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Jun 26, 2026, 5:10 PM
FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances TrialBenzinga · Jun 24, 2026, 12:40 PM
Market-Moving News for June 24thBenzinga · Jun 24, 2026, 11:20 AM
CalciMedica Announces Private Placement Worth Up To ~$49M In Gross ProceedsBenzinga · Jun 24, 2026, 11:15 AM
CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With AuxoraBenzinga · Jun 24, 2026, 11:10 AM